Lv2
140 积分 2026-01-26 加入
Biologically explicable multimodal model predicting local tumor progression and tumor invasiveness of hepatocellular carcinoma
6天前
已完结
Epidemiology of myasthenia gravis
1个月前
已完结
Treatment with Ex Vivo Expanded Autologous Regulatory CD4+CD25+Foxp3+CD127low T Cells Restores the Balance of the Immune System in Patients with Remitting Multiple Sclerosis
1个月前
已完结
A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy—case report and literature review
1个月前
已完结
Design of KYSA-6, a Phase 2, Open-label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis (P7-11.034)
1个月前
已关闭
OP0032 Treatment of Refractory Systemic Lupus Erythematosus with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
1个月前
已关闭
Efficacy and Safety of Autologous BCMA-directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Placebo-controlled Trial (S34.002)
1个月前
已关闭
Publication Only
1个月前
已关闭
Landmark Long-Term Remission Achieved with ICG318, a BCMA-CD19 Armored Compound CAR T-cell Therapy, in Refractory Systemic Lupus Erythematosus/Lupus Nephritis with Follow-up Approaching 6 Years
1个月前
已关闭
Update on the Phase 2 Part of Kysa-6, an Open-Label, Single-Arm, Multicenter Study of Kyv-101, a Fully Human CD19 Chimeric Antigen Receptor T-cell Therapy in Generalized Myasthenia Gravis
1个月前
已关闭
皖公网安备34019202002308
